Cabozantinib after progression of kidney cancer improves survival

In a recent study, the use of cabozantinib after progression of renal cell carcinoma (RCC) was assessed. Forty-five (45) patients continued with treatment with cabozantinib after their disease had progressed, and 44 patients switched to cabozantinib. Nearly 60% of patients had been treated with two or more prior treatments. Of these patients, most (85%) had […]

read more

ASCO GU 2021: Long-term follow-up of kidney cancer patients on nivolumab plus ipilimumab combination

Long-term follow-up data from the CheckMate-214 study of the nivolumab plus ipilimumab combination in untreated, advanced clear cell kidney cancer patients were presented at the virtual American Society for Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) in San Francisco this weekend. Patients were followed for at least 4 years after treatment with nivolumab plus ipilimumab […]

read more
Showing all 2 results